Skip to main content

AMWA Advocacy Update: AMWA requests changes to labeling of low dose estrogen products

October 09, 2015– The American Medical Women’s Association (AMWA) agrees that the boxed warning on the package label for low-dose vaginal estrogen discourages clinicians from prescribing the product and women from taking it even after purchase. The current boxed warning, states “WARNING: ENDOMETRIAL CANCER, CARDIOVASCULAR DISORDERS, BREAST CANCER, and PROBABLE DEMENTIA. This wording is not appropriate for low dose estrogen products used to treat vulvovaginal atrophy (VVA). This condition, also known as genitourinary syndrome of menopause, is a common and progressive condition that adversely affects the health and quality of life of many postmenopausal women. To improve the quality of life and provide appropriate treatment and education, we join the NAMS, and other organizations in requesting that the labeling for low dose estrogen products be changed and the current warning be dropped.

Click here to fill out the petition

Close Menu